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Dermal soft-tissue augmentation using a ﬁller is a technique widely used for facial cosmetic enhance-
ment. However, potential complications following facial cosmetic injections have heightened the pos-
sibility of iatrogenic visual loss. We report two cases of severe ocular complications after nasal cosmetic
enhancement. Both cases had poor visual outcomes in spite of emergency management. The second
patient is a rare case with bilateral anterior ischemic optic neuropathy after dermal soft-tissue
augmentation. The visual outcome was correlated with the location and the extent of the arterial
embolization. Unfortunately, there is still no standard treatment protocol for vision-threatening com-
plications. Clinicians should always keep in mind that embolic arterial occlusion may occur after
augmentation.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Dermal soft-tissue augmentation using a ﬁller is a widely used
technique for modern facial cosmetic enhancement due to its
convenience, high predictability, and good results. However, a
serious complication of arterial embolization can occur due to
accidental injection of the ﬁller material into small vessels leading
to tissue necrosis. In recent years, complications after facial
cosmetic injections have heightened the awareness of the possi-
bility of iatrogenic visual loss. Most previous case reports have
shown fair visual recovery and spontaneous resolution of the
embolization episodes.
Herein, we present two cases whereby severe ocular compli-
cations occurred after nasal cosmetic enhancement. One patient
suffered from unilateral irreversible visual loss leading to eyeball
atrophy. The other patient encountered bilateral ischemic optic
neuropathy and diffuse chorioretinal ischemia in one eye. These
cases serve as a reminder that adverse events after cosmeticinterest in any materials or
ology, National Taiwan Uni-
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ciety of Taiwan. Published by Elseenhancement can cause permanent ocular complications and can
occur bilaterally.
2. Case reports
2.1. Case 1
The ﬁrst case was a 47-year-old female hepatitis B virus carrier
with normal liver functions, who denied having a previous history
of other systemic diseases. She received a facial calcium hydroxyl-
apatite injection in the glabellar area for augmentation rhinoplasty.
She complained of a headache immediately while the injectionwas
being given. Sudden left eye blindness and general weakness
developed 10 minutes after the injection. Severe headache and left
ocular pain occurred 1 hour later, and she was sent to our hospital.
In the emergency room, there was no light perception in her
left eye, with retinal cherry-red spots, moderate ptosis, and limited
eye movements. The tentative diagnosis was central retinal artery
occlusion and ophthalmoplegia of the left eye. Although the intra-
ocular pressure of her left eye was within normal limits,
we performed anterior chamber paracentesis and administered
timolol and acetazolamide in order to push the emboli to the distal
side. A neurological examination revealed mild right central facial
palsy and right limb weakness. Brain magnetic resonance imaging
showed multiple small infarctions with intracranial hemorrhages in
the left cerebral hemisphere (Fig. 1A). Carotid duplex showed anvier Taiwan LLC. All rights reserved.
Fig. 1. Case 1: (A) Brain magnetic resonance imaging (T2 FS) showing multiple small infarctions and multiple intracranial hemorrhages in the left cerebral hemisphere. (B) The
cornea of the left eye 1 day after the injection became edematous. (C) The corneal edema of the left eye is markedly improved 3 weeks after the injection. (D) Fundus photography of
the left eye 3 weeks after the injection showing total exudative retinal detachment with retinal atrophy.
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admission, she received hydration under the impression of multiple
artery embolizations; meanwhile, oral antiplatelet agents were also
given. Systemic work-ups for diabetes, rheumatologic disorders, and
hypercoagulation status were done, but all ﬁndings were negative.
Orbital infarction syndrome developed 1 day after the calcium
hydroxylapatite injection (Fig. 1B). The cornea became edematous,
and a mild anterior chamber reaction was noted. Her left eye
became hypotonous. The fundus was blurred due to an edematous
cornea; however, the retina was generally pale. We then added
topical betamethasone. Multiple reticulated, erythematous-to-
violaceous ulcerative skin lesions were noted over the glabella,
perinasal, and periorbital areas. The ocular pain and oph-
thalmoplegia gradually improved (Fig. 1C), but the retina eventu-
ally became totally detached (Fig. 1D). No light perception in her
left eye was noted during follow-up.2.2. Case 2
In the second case, a 33-year-old female with no history of
systemic diseases received a dermal calcium hydroxylapatite in-
jection for nasal bridge augmentation. Sudden eye pain and visual
impairment occurred in the left eye during the injection. Bilateral
lower visual ﬁeld defects were noted several hours later, and she
was sent to our hospital.
The initial visual acuity was 20/60 in the left eye and 20/20 in
the right eye. Fundoscopy of the right eye was relatively normal
(Fig. 2A). However, the fundus of the left eye showed both diffuse
drusen-like lesions in the retina and diffuse crystal-like lesions in
the level of the choroid. Retinal whitening was seen around the disc
with a radial peripapillary capillary distribution (Fig. 2B). A visual
ﬁeld examination revealed altitudinal visual ﬁeld defects in both
eyes and generalized depression over the left eye (Fig. 3). No
extraocular muscle limitation was noted. The tentative diagnosiswas bilateral anterior ischemic optic neuropathy and chorioretinal
vascular occlusion over the left eye. She received hyperbaric oxygen
therapy, systemic low-dose steroids, antiaggregants, and topical
and oral antiglaucomatous agents.
Five days later, a follow-up fundoscopy of the left eye showed
disc swelling, extensive small white embolic particulates in the
choroidal vessels, and peripapillary retinal whitening with a ﬂame-
shaped intraretinal hemorrhage (Fig. 2C). The intraocular pressure
was only 5 mmHg over the left eye, with a visual acuity of 20/20 in
the right eye, and 20/50 in the left eye.
Because the ocular condition of the patient did not show
obvious improvement, systemic treatments, including systemic
steroid and anticoagulants, were gradually tapered. The topical
steroid treatment was maintained, but no apparent visual im-
provement was noted. The antiglaucomatous agents were also
discontinued due to persistent intraocular pressure below the
normal range (around 5e10 mmHg) after 2 months of treatment.
Two months later, the visual acuity had decreased to 20/200 in
the left eye and 20/20 in the right eye. The retinal hemorrhage over
the left eye resolved; however, the crystal-like linear deposition in
the choroidal layer persisted, and the vessels became attenuated.
Bilateral optic discs were pale (Fig. 2D). A visual evoked potential
examination revealed a low amplitude waveform with prolonged
latency over the left eye and a relatively normal waveform over the
right eye. A follow-up visual ﬁeld test still showed altitudinal visual
ﬁeld defects in both eyes and generalized depression in the visual
ﬁeld of the left eye.3. Discussion
Calcium hydroxylapatite is composed of microspheres of a syn-
thetic bone suspended in a methylcellulose gel matrix. It is thicker
than hyaluronic acids and has longer lasting effects for facial
correction.1 It is widely used to treat severe or moderate wrinkles of
Fig. 2. Case 2: (A) Fundus photography of the right eye showing a relatively normal retinal presentation. (B) Ocular fundoscopy over the left eye revealed diffuse drusen-like lesions
in the retina and diffuse crystal-like lesions in the level of the choroid. Retinal whitening around the disc is seen in a radial peripapillary capillary distribution. (C) Follow-up
fundoscopy of the left eye 5 days later shows disc swelling, extensive small white embolic particulates in the choroidal vessels, and retinal whitening with a ﬂame-shaped
intraretinal hemorrhage. (D) The retinal hemorrhage over the left eye resolved; however, the crystal-like linear deposition in the choroidal layer persisted, and the vessels
became attenuated. The optic discs were pale.
Fig. 3. Case 2: Visual ﬁeld examination 2 days after the injection reveals altitudinal visual ﬁeld defects in both eyes, and generalized depression over the left eye.
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particles can act as potential emboli, which can cause small vessel
occlusions if incidental intravascular injection occurs. In Case 1 of the
present study, the embolization resulted inmultiple small infarctions
with intracranial hemorrhages in the left cerebrum, oph-
thalmoplegia, central retinal artery occlusion, orbital ischemic syn-
drome, discoloration, and necrosis of the skin after injection of the
ﬁller into the glabellar area. Previous reports have hypothesized that
the injection pressure might retroactively push ﬁller materials into
arteries and create multiple distal site occlusions.2e4 However, in
Case 2, the ﬁller with calcium hydroxylapatite not only resulted in
acute vision damage, but also progressive choroidal and retinal vessel
occlusion caused gradual visual loss. The most common dosage of
dermal ﬁllers for nasal bridge augmentation is about 1.0e1.5 mL
among Asians. According to surgeon statements, both of the patients
in this study complained of eye pain and blurred vision when
< 1.0mL ﬁller has been injected, and therefore complications are not
likely to be dose related.
Although embolic arterial occlusion after cosmetic procedures is
rare, the inﬂuence on vision is devastating. Risk factors include the
site of injection, techniques used during the injection, and the skill
of the practitioner.5 We inspected previous case reports and none
addressed the relationship between systemic diseases and com-
plications. The glabellar area is one of the most common sites
associated with severe ocular complications after injection. Many
ﬁller materials have been reported to cause blindness after
cosmetic injections, including fat tissue, parafﬁn, silicone oil, bovine
collagen, hyaluronic acid, polymethylmethacrylate, and calcium
hydroxylapatite.6 The mechanism of orbital ischemic syndrome
may be due to direct entry of the needle tip into the branches of the
lateral nasal and dorsal nasal arteries. The ﬁller materials may then
enter the ophthalmic artery and occlude the central retinal, short,
and long posterior ciliary arteries. Another possibility is that the
ﬁller materials are injected into Kiesselbach’s area, an area of
anastomosis between the internal and external carotid arteries, and
then enter the central retinal artery through the anterior ethmoidal
artery. Blockage of the long posterior ciliary artery can cause ciliary
body ischemia leading to ocular hypotony, which has been reported
to be associated with decreased aqueous humor production.7
Ophthalmoplegia occurs due to the involvement of the muscular
branch of the ophthalmic artery. In addition, thematerials may ﬂow
in a retrograde manner from the ophthalmic artery into the intra-
cranial middle cerebral artery through the internal carotid artery,
resulting in cerebral infarction and distal embolismwith secondary
hemorrhagic transformation.Various protocols have been reported with regards to the man-
agement of skin lesions, including immediate discontinuation of the
injection and gently massaging the affected area, applying warm
water on gauze, nitroglycerine paste, injecting hyaluronidase (for
hyaluronic acid gel), and low molecular weight heparin.5 However,
no protocols currently exist for ocular complications. In previous
reports, several different individualized treatments were applied,
including medical and surgical approaches such as administration
of systemic steroids, carbonic anhydrase inhibitor, vasodilators,
antiplatelet agents, performing ocular massage, and anterior
chamber paracentesis.6 However, the visual prognosis was still re-
ported to be very poor despite the management, and < 10% of the
patients (3 of 32 cases) achieved visual recovery.6 If ocular ischemic
syndrome develops, topical steroids can be given to suppress
anterior segment inﬂammation, along with cycloplegics to stabilize
the blood-aqueous barrier and prevent spontaneous hyphema. In
cases of chronic ischemia, preventing neovascularization is very
important. Methods of prevention include aspiration prior to the
injection, injecting superﬁcially andmedially, limiting the bolus size
and syringe size, and avoiding sharp needles.
In conclusion, facial calcium hydroxylapatite injection is a
widely performed dermal soft-tissue augmentation procedure,
however it may cause central retinal artery occlusion, ocular and
orbital ischemic syndrome, and chronic retinal and choroidal vessel
occlusion. Although it is a rare adverse event, clinicians should be
aware of the potential risk of embolization when injecting dermal
ﬁllers in the glabellar area.References
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